Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.
All answers match the protocol.
Population and eligibility
Design
Patient burden
Operations
Environment
Build a site
A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.
Poland recruits fastest per site, at 0.130 a month
Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted
Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.
Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).
Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).
Show data
| Factor | United States | United Kingdom | Spain | Poland |
|---|---|---|---|---|
| Therapeutic area | 0.450 | 0.450 | 0.450 | 0.450 |
| Country | 0.338 | 0.383 | 0.450 | 0.630 |
| Site type | 0.341 | 0.378 | 0.441 | 0.663 |
| Track record | 0.295 | 0.327 | 0.381 | 0.573 |
| Protocol and population | 0.162 | 0.180 | 0.210 | 0.315 |
| Patient acceptability | 0.089 | 0.099 | 0.115 | 0.173 |
| Competing trials | 0.067 | 0.074 | 0.087 | 0.130 |
What this design does to the sites needed
To finish by May 2029 with 85% confidence, this design needs about 142 sites, the same as the protocol as written.
| Country | Per site per month, protocol as written | With this design | Change | Sites needed, protocol | With this design |
|---|---|---|---|---|---|
| United States | 0.067 | 0.067 | – | 0 | 0 |
| United Kingdom | 0.074 | 0.074 | – | 30 | 30 |
| Spain | 0.087 | 0.087 | – | 71 | 71 |
| Poland | 0.130 | 0.130 | – | 41 | 41 |
Risks these answers switch on
Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.
Protocol and design
PD-01Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) Grade A
- Effect
- Negative; eligible pool ×0.48 to 0.53 against broadened criteria, with the hazard ratio unchanged or better.
- What helped
- ASCO-Friends modernised criteria and the FDA 2020 to 2026 guidances; data-driven criteria; adoption of 54 to 93% by criterion in NCI CTEP protocols.
- What did not
- Laboratory and washout exclusions carried forward unchanged across phases and years.
- Sources
- Harvey 2021; Liu 2021; Kim 2017 and 20212; Unger 2019
PD-02Number of eligibility criteria and complexity growth Grade B
- Effect
- Negative; more criteria independently associated with poor accrual (p = 0.013); complex trials randomise 59% of screened against about 75%.
- What helped
- Upstream protocol feasibility review and benchmarking against Tufts norms.
- What did not
- not found
- Sources
- Carlisle 2015; Getz 2014; Getz 2023
EB-01Overestimated eligible pool (Lasagna's law) Grade B
- Effect
- Negative; the commonest cause of recruitment-related discontinuation, first-quarter recruitment slower than planned in 63% of UK trials, and realistic yield quoted second-hand as one-tenth to one-third of the estimate.
- What helped
- Internal pilot with an explicit projection equation and stop-go review (Bertram 2019, descriptive); pre-trial accrual assessment (Schroen 2010: 67% against 47% sufficient accrual); evidence-based feasibility (CTTI 2018, no numbers).
- What did not
- A formal pilot phase as such (McDonald 2006: OR 1.09, no association); time extensions alone (Sully 2013: 55% against 54% reached target).
- Sources
- Briel 2016; McDonald 2006; van der Wouden 2007; Lasagna 1979; Feinstein 2001 via Bogin 2022
EB-04Restrictive eligibility criteria and protocol complexity Grade B
- Effect
- Negative; more eligibility criteria associated with accrual failure (p=0.013), 21.5% of cancer patients ineligible for an available trial, procedure counts rising 6.5 to 10.5% a year, and tissue sample required OR 1.26 with a CI including 1.
- What helped
- CTTI framework recommends limiting complexity and realistic eligibility (not quantified).
- What did not
- not found
- Sources
- Carlisle 2015; Unger 2019; Getz 2008; Getz 2018; Bennette 2016
PB-02Eligibility criteria exclude patients (comorbidity, age, performance status, language) Grade A
- Effect
- 21.5% (10.9 to 34.6) of patients with an open trial are ineligible; any comorbidity cuts participation odds to 0.76; 81.3% of high-impact RCTs exclude common conditions; 19% of US trials require English.
- What helped
- Broadening criteria: dropping the comorbidity restrictions ASCO recommends removing could add up to 6,317 registrations a year; translation widens the pool.
- What did not
- not found
- Sources
- Unger 2019 JNCI; Unger 2019 JAMA Oncol; Van Spall 2007; Muthukumar 2021
PD-15Comorbidity exclusions Grade B
- Effect
- Negative; 65.6% of cancer patients have at least one comorbidity; participation OR 0.76.
- What helped
- Remove ASCO-flagged comorbidity restrictions, simulated to add up to 6,317 US registrations a year.
- What did not
- not found
- Sources
- Unger 2019 JAMA Oncology
PB-10Older adults under-enrolled Grade A
- Effect
- People aged 65 and over were 25% of trial entrants against 63% of cancer patients; trial median age 6.49 years below the population; 70 and over are 24% of FDA-registered trial participants against 42% of the cancer population.
- What helped
- Coverage policy raised 65 and over accrual (Unger 2006); broader eligibility and fewer performance-status cut-offs narrow the gap (Ludmir 2019).
- What did not
- Physician geriatric education, cluster RCT across 126 institutions, no effect (Kimmick 2005).
- Sources
- Hutchins 1999; Ludmir 2019; Sedrak 2021; FDA Snapshots 2024
PD-05Placebo or no-added-treatment control arm Grade B
- Effect
- Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
- What helped
- All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
- What did not
- not found
- Sources
- Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
- Effect
- Negative association only; poor accrual 23% against 16%.
- What helped
- not found
- What did not
- not found
- Sources
- Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
- Effect
- Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
- What helped
- Open or PROBE design where scientifically acceptable.
- What did not
- User-tested information leaflets added 1 point, no effect.
- Sources
- Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
- Effect
- Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
- What helped
- Open-label or pragmatic design where scientifically acceptable (high certainty).
- What did not
- not found
- Sources
- Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-09Washout periods and concomitant-medication exclusions Grade C
- Effect
- Negative and qualitative; IBD patients deterred; criteria often arbitrary.
- What helped
- Remove arbitrary washouts, as the FDA final guidance of July 2026 requires.
- What did not
- not found
- Sources
- Harvey 2021 washout group; Liu 2021; Uzzan 2023
PD-10Run-in period before randomisation Grade C
- Effect
- Negative for randomised yield; narrows the population and overstates benefit.
- What helped
- Use only where there is a scientific need.
- What did not
- not found
- Sources
- Pablos-Méndez 1998
PD-03Procedural and visit burden (visits, blood draws, questionnaires) Grade B
- Effect
- Negative; burden score predicts screen failure, trial duration, and amendments (p < 0.01); oncology plans 29 visits against 16.
- What helped
- Score burden at design; prune non-core procedures, which are 22 to 25% of all procedures.
- What did not
- Sites rate decentralised trials as more burdensome for patient-facing procedures.
- Sources
- Smith 2021; Dirks 2025; Getz 2023
S-24Protocol complexity and site burden Grade B
- Effect
- Negative: procedures up 40.6%, sites per protocol up 60.1%, and enrolment duration up 36.9% (2010 to 2020); 70% of site staff say trials are much harder; about one-third of data collected is non-core.
- What helped
- Remove non-core data and procedures. Take site input on design.
- What did not
- not found
- Sources
- Clinical Trial Vanguard 2024; WCG 2024; Tufts CSDD 2022; PharmaVoice 2025
EB-17Follow-up burden and duration Grade C
- Effect
- Negative; trials with final follow-up beyond 18 months recruit at 0.71 per centre per month against 1.29 for follow-up within a month (p=0.054); time commitment is a key deterrent in the qualitative synthesis.
- What helped
- Reducing visit burden (CTTI, not quantified).
- What did not
- not found
- Sources
- Jacques 2022; Houghton 2020
PD-20Decentralised elements Grade C
- Effect
- Unclear; modelled value only; sites split on whether they add or remove burden.
- What helped
- Hybrid elements for follow-up visits.
- What did not
- A fully remote trial under-recruited despite a very large outreach funnel.
- Sources
- FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
PD-04Substantial protocol amendments Grade B
- Effect
- Negative; 76% of protocols amended, 3.3 each, 260 days to implement, 215 days of version mismatch, enrolment against plan reduced; $141,000 to $535,000 each.
- What helped
- Governance review before approval, since about 40% of amendments occur before first patient first dose.
- What did not
- Amendments raise screening volume but not enrolment against plan.
- Sources
- Getz 2016; Getz 2024; Botto 2024; Getz 2014
S-14Protocol amendments before and after activation Grade B
- Effect
- Negative on time: 24% of studies amended before activation, a 4 to 6 week delay typical and 10 weeks or more for about 20% of centres, 260 days to implement an amendment, and 82% of Phase III protocols amended.
- What helped
- Finalise the protocol before feasibility. Take site input on design (46% of sites ask for it).
- What did not
- not found
- Sources
- Clinical Trial Vanguard 2024; AACI 2026
Site
S-06Site type: activation speed Grade A
- Effect
- Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
- What helped
- Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
- What did not
- Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
- Sources
- Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
S-07Site type: enrolment rate Grade C
- Effect
- Positive for research-focused sites: 41% better enrollers than practice-focused sites (72 protocols); in-network investigators about 25% more; network sites may have an advantage on a small sample.
- What helped
- Select sites with dedicated research infrastructure and a recruitment plan.
- What did not
- not found
- Sources
- Getz 2011; Dirks, Chambers, and Getz 2026; Yang 2018
S-05New-to-sponsor site Grade B
- Effect
- Negative on time: 28 to 30% of sites are new to the sponsor and initiation takes about 10 weeks longer; sites with 6 to 10 trials' experience are more likely to hit target; no measured rate penalty.
- What helped
- Repeat-site preference where the patient pool allows. Master agreements and central IRB.
- What did not
- not found
- Sources
- Getz 2011; WCG 2018; Getz 2016; Miseta 2017
PM-02Academic and hospital sites, and sites new to the sponsor, take longer to activate Grade B
- Effect
- Delays activation by months: 8.1 to 9.4 months for academic medical centres against 4.4 to 4.8 for independent sites, 12.9 against 7.9 months from pre-study visit to first patient, and 35.6 weeks for new sites against 25.7 for repeat sites.
- What helped
- not found
- What did not
- not found
- Sources
- WCG Data Intelligence 2023 to 2025; Tufts CSDD 2012; Tufts CSDD 2018
S-21Competing trials Grade B
- Effect
- Negative when the eligible pool is scarce: OR 1.88 (1.32 to 2.68) for low accrual per competing trial per 10,000 eligible patients per year; no effect when the pool is large; 3,042 immuno-oncology trials sought 577,076 patients.
- What helped
- Redirect referrals to non-overlapping sites and re-engage the PI (anecdotal). Choose indications and regions with slack.
- What did not
- Adding sites into the same saturated pool.
- Sources
- Bennette 2016; Hutchinson 2022; Tang 2018; ClinOops 2026
EB-02Competing trials for the same patients Grade A
- Effect
- Negative; OR 1.88 (95% CI 1.32 to 2.68) for low accrual per additional competing trial per 10,000 eligible patients per year, with low-accrual trials facing a median 4.4 against 2.9 competing trials.
- What helped
- Not tested as an intervention; Bennette's model identified a top-decile risk group with 52% low accrual, usable for site and country selection.
- What did not
- not found
- Sources
- Bennette 2016; Schroen 2011
SH-30Competing trials at a site Grade D
- Effect
- Not found; practitioner belief that concurrent trials dilute per-trial enrolment is widespread but anecdotal.
- What helped
- not found
- What did not
- not found
- Sources
- not found (practitioner belief, anecdotal)
Sponsor, CRO and model
PD-18No patient and public involvement in design Grade A
- Effect
- Positive when present; enrolment OR 1.16 (1.01 to 1.34); lived-experience involvement OR 3.14, exploratory.
- What helped
- Patient and public involvement in protocol design.
- What did not
- Retention was not improved (OR 1.16, 0.33 to 4.14).
- Sources
- Crocker 2018
EB-23Patient and public involvement in design Grade B
- Effect
- Positive; PPI interventions associated with higher enrolment (OR 1.16, 1.01 to 1.34), larger with lived-experience involvement (OR 3.14 against 1.07, exploratory); PRioRiTy question 3 asks exactly this.
- What helped
- Involving people with lived experience of the condition in planning.
- What did not
- Retention effect inconclusive (OR 1.16, 0.33 to 4.14).
- Sources
- Crocker 2018; Healy 2018
PD-21No upstream protocol feasibility review Grade B
- Effect
- Negative; 23 to 45% of amendments avoidable and about 40% occur before first patient first dose.
- What helped
- Cross-functional governance review; the CTTI three-area framework; critical-to-quality factors at planning.
- What did not
- not found
- Sources
- Getz 2014, 2016, and 202423; Huang 2018; ICH E8(R1)
EB-18Protocol amendments Grade B
- Effect
- Negative; 57% of protocols had at least one substantial amendment, 45% avoidable; amended protocols recruited longer and enrolled fewer than planned; median direct cost $535,000 in Phase III; over 40% amend before first patient visit, delaying about four months (secondary).
- What helped
- Protocol governance and simplification (not quantified).
- What did not
- not found
- Sources
- Getz 2016; Getz 2011 via Fogel 2018
S-18Technology burden Grade B
- Effect
- Negative on site time, unquantified for enrolment: 60% of sites use 20 or more systems daily, about 10 to 12 applications per site in 2015, 46% say too many separate technologies and 74% cite login tracking (2020), 40% of sites spend 5 to 15 hours per month per study on unpaid training, and 19% rank sponsor technology a top challenge.
- What helped
- Accept site-preferred systems. Consistent technology across a sponsor's studies. Paid training.
- What did not
- not found
- Sources
- WCG 2024; SCRS 2023 Site Landscape; Bechtel 2024; Florence 2024; SCRS 2020